
|Videos|December 10, 2016
Takeaways From TransATAC Trial on Comparing Prognostic Signatures
Author(s)William J. Gradishar, MD
William J. Gradishar, MD, deputy director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of Medicine, discusses the takeaways from the TransATAC trial, which was a comprehensive comparison of prognostic signatures in breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
3
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
4
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
5









































